Literature DB >> 29097168

Synthesis and biological evolution of hydrazones derived from 4-(trifluoromethyl)benzohydrazide.

Martin Krátký1, Szilvia Bősze2, Zsuzsa Baranyai2, Jiřina Stolaříková3, Jarmila Vinšová4.   

Abstract

Reflecting the known biological activity of isoniazid-based hydrazones, seventeen hydrazones of 4-(trifluoromethyl)benzohydrazide as their bioisosters were synthesized from various benzaldehydes and aliphatic ketones. The compounds were screened for their in vitro activity against Mycobacterium tuberculosis, nontuberculous mycobacteria (M. avium, M. kansasii), bacterial and fungal strains. The most antimicrobial potent derivatives were also investigated for their cytostatic and cytotoxic properties against three cell lines. Camphor-based molecule, 4-(trifluoromethyl)-N'-(1,7,7-trimethylbicyclo[2.2.1]heptan-2-ylidene)benzohydrazide, exhibited the highest and selective inhibition of M. tuberculosis with the minimum inhibitory concentration (MIC) of 4 µM, while N'-(4-chlorobenzylidene)-4-(trifluoromethyl)benzohydrazide was found to be superior against M. kansasii (MIC = 16 µM). N'-(5-Chloro-2-hydroxybenzylidene)-4-(trifluoromethyl)benzohydrazide showed the lowest MIC values for gram-positive bacteria including methicillin-resistant Staphylococcus aureus as well as against two fungal strains of Candida glabrata and Trichophyton mentagrophytes within the range of ≤0.49-3.9 µM. The convenient substitution of benzylidene moiety at the position 4 or the presence of 5-chloro-2-hydroxybenzylidene scaffold concomitantly with a sufficient lipophilicity are essential for the noticeable antimicrobial activity. This 5-chlorosalicylidene derivative avoided any cytotoxicity on two mammalian cell cultures (HepG2, BMMΦ) up to the concentration of 100 µM, but it affected the growth of MonoMac6 cells.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-(Trifluoromethyl)benzohydrazide; Antibacterial activity; Antifungal activity; Cytostasis; Cytotoxicity; Hydrazone; Mycobacterium tuberculosis; Nontuberculous mycobacteria

Mesh:

Substances:

Year:  2017        PMID: 29097168     DOI: 10.1016/j.bmcl.2017.10.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  N-Alkyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides and Their Analogues: Synthesis and Multitarget Biological Activity.

Authors:  Martin Krátký; Zsuzsa Baranyai; Šárka Štěpánková; Katarína Svrčková; Markéta Švarcová; Jiřina Stolaříková; Lilla Horváth; Szilvia Bősze; Jarmila Vinšová
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

2.  Hydrazones of 4-(Trifluoromethyl)benzohydrazide as New Inhibitors of Acetyl- and Butyrylcholinesterase.

Authors:  Martin Krátký; Katarína Svrčková; Quynh Anh Vu; Šárka Štěpánková; Jarmila Vinšová
Journal:  Molecules       Date:  2021-02-13       Impact factor: 4.411

3.  Catalyst- and Additive-Free C(sp3)-H Functionalization of (Thio)barbituric Acids via C-5 Dehydrogenative Aza-Coupling Under Ambient Conditions.

Authors:  Goutam Brahmachari; Anindita Bhowmick; Indrajit Karmakar
Journal:  ACS Omega       Date:  2022-08-17

4.  Synthesis and Characterization of Novel Hydrazone Derivatives of Isonicotinic Hydrazide and Their Evaluation for Antibacterial and Cytotoxic Potential.

Authors:  Muhammad Abdullah Shah; Ala Uddin; Muhammad Raza Shah; Imdad Ali; Riaz Ullah; Peer Abdul Hannan; Hidayat Hussain
Journal:  Molecules       Date:  2022-10-10       Impact factor: 4.927

5.  4-Aminobenzoic Acid Derivatives: Converting Folate Precursor to Antimicrobial and Cytotoxic Agents.

Authors:  Martin Krátký; Klára Konečná; Jiří Janoušek; Michaela Brablíková; Ondřej Janďourek; František Trejtnar; Jiřina Stolaříková; Jarmila Vinšová
Journal:  Biomolecules       Date:  2019-12-19

6.  Novel Aminoguanidine Hydrazone Analogues: From Potential Antimicrobial Agents to Potent Cholinesterase Inhibitors.

Authors:  Martin Krátký; Šárka Štěpánková; Klára Konečná; Katarína Svrčková; Jana Maixnerová; Markéta Švarcová; Ondřej Janďourek; František Trejtnar; Jarmila Vinšová
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.